Table 1 Therapies in clinical development for treatment of IgAN
From: Role of telitacicept in the treatment of IgA nephropathy
Agent | Target | Format | Mechanism of action | Stage in IgAN to date | References |
|---|---|---|---|---|---|
Rituximab | CD20 | Monoclonal antibody | Depletes CD20 B cells | Phase 4 | NCT00498368 |
Belimumab | BAFF | Monoclonal antibody | Inhibits activation of B cells | None | 44 |
Narsoplimab | MASP-2 | Monoclonal antibody | Inhibits complement lectin pathway activation | Phase 3 | NCT03608033 |
Telitacicept | BAFF and APRIL | Fusion protein/antibody | Inhibits maturation and activation of B cells | Phase 2 | NCT04291781 |
Atacicept | BAFF and APRIL | Fusion protein/antibody | Inhibits maturation and activation of B cells | Phase 3 | NCT04716231 |
Sparsentan | ETAR and AT1R | Non-immunosuppressive, single-molecule | Vasodilator effects | Phase 3 | NCT03762850 |